In vivo evaluation of Mehozumab‐DM1 is conducted in a CRISPR‐mediated PTEN and TP53 mutation cynomolgus monkey liver cancer model, which is poorly responsive to sorafenib treatment. The gene discussed is TP53; the disease is liver cancer.